New York esophageal squamous cell carcinoma 1 (NY-ESO-1) peptide-HLA complex (NY-ESO-1/HLA complex)

New York esophageal squamous cell carcinoma 1 (NY-ESO-1) is a prominent cancer-testis antigen (CTA) encoded by the CTAG1B gene (UniProt P78358). Under physiological conditions, its expression is restricted to the germ cells of the testis and placental trophoblasts, which do not express MHC class I molecules, making it effectively invisible to the immune system in healthy tissues (PubMed: 16551957). However, NY-ESO-1 is frequently re-expressed in a wide range of cancers, including synovial sarcoma, melanoma, and multiple myeloma, where it is processed into peptides and presented on the cell surface by Human Leukocyte Antigen (HLA) molecules (PubMed: 24942756). This peptide-HLA complex is a highly specific target for immunotherapy, particularly TCR-engineered T-cell (TCR-T) therapies like afamitresgene autoleucel, which are designed to recognize the NY-ESO-1/HLA-A*02 complex (FDA, 2024). By targeting this complex, drugs can induce potent, antigen-specific cytotoxic T-cell responses against tumor cells while sparing normal somatic tissues. Despite its promise, therapeutic success depends on the patient's HLA type and the density of antigen expression, and risks include cytokine release syndrome and potential cross-reactivity with similar endogenous peptides (PubMed: 31092554).

Other names

CTAG1BCancer/testis antigen 1BLAGE-2NY-ESO-1NY-ESO-1 peptide-MHC complexNY-ESO-1/MHC complex

The mechanism of action involves the recognition of the NY-ESO-1 peptide (typically the 157-165 SLLMWITQC epitope) presented on HLA-A*02 by engineered T-cell receptors (TCRs), leading to the formation of an immunological synapse, T-cell activation, and the subsequent release of cytotoxic molecules like perforin and granzymes to induce apoptosis in tumor cells (PubMed: 24942756, FDA 2024).